Advertisement
Posters CLINICAL TRIALS & OUTCOME MEASURES| Volume 21, SUPPLEMENT 2, S105, October 2022

180 First-in-human study to evaluate safety, tolerability, and pharmacokinetics of GDC-6988 (ETD002), a selective inhaled potentiator of the TMEM16A chloride channel

DOI:https://doi.org/10.1016/S1569-1993(22)00870-0
180 First-in-human study to evaluate safety, tolerability, and pharmacokinetics of GDC-6988 (ETD002), a selective inhaled potentiator of the TMEM16A chloride channel
Previous Article179 Inflammation-based scoring systems and ratios to identify people with cystic fibrosis at risk for intravenous antibiotic therapy
Next Article181 Estimating personalized lung function trends from routine clinical care to facilitate analysis of daily data capture using remote technologies
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S1569-1993(22)00870-0

      Copyright

      © 2022 European Cystic Fibrosis Society. All rights reserved. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX